# ATHE catalysts: ALTERITY THERAPEUTICS LTD PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/athe/catalysts

> ALTERITY THERAPEUTICS LTD (ATHE) has 2 upcoming catalysts. The next is the ATH434 primary completion, July 2029.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, half-year only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Company

| Field | Value |
| --- | --- |
| Name | ALTERITY THERAPEUTICS LTD |
| Ticker | ATHE (Nasdaq) |
| SEC CIK | 1131343 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/athe |

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| July 17, 2024 | [ATH434 interim data readout](https://sec-api.dev/pdufa/ath434) | ATHE | advanced MSA | completed, positive | "17 July 2024, Alterity reported positive interim data from the ATH434-202 trial." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1131343/000121390025018328/ea023254702ex99-1_alterity.htm)) |
| July 28, 2024 | [ATH434 topline data readout](https://sec-api.dev/pdufa/ath434) | ATHE | multiple system atrophy | completed, positive | "- 28 July 2024: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced positive topline data from the ATH434-202 open-label Phase 2 clinical trial in individuals with multiple system atrophy (MSA)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1131343/000121390025067901/ea025038601ex99-1_alterity.htm)) |
| Oct 2024 | [ATH434 interim data readout](https://sec-api.dev/pdufa/ath434) | ATHE |  | completed, positive | "October 2024, Alterity announced the presentation of positive interim data from the ATH434-202 trial as both a late-breaking oral presentation and poster session entitled "Preliminary Efficacy and Safety of ATH434 in Multiple System Atrophy" at the MDS meeting." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1131343/000121390025018328/ea023254702ex99-1_alterity.htm)) |
| January 30, 2025 | [ATH434 topline data readout](https://sec-api.dev/pdufa/ath434) | ATHE |  | completed, positive | "On 30 January 2025, Alterity announced the positive topline results led by robust clinical efficacy." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1131343/000121390025037102/ea024013201ex99-1_alterity.htm)) |
| Feb 2025 | [ATH434 topline data readout](https://sec-api.dev/pdufa/ath434) | ATHE |  | scheduled | "Topline data for ATH434-201 randomized, double-blind Phase 2 clinical trial on track for expected release by early February 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1131343/000121390025006208/ea022862501ex99-1_alterity.htm)) |
| July 28, 2025 | [ATH434 topline data readout](https://sec-api.dev/pdufa/ath434) | ATHE |  | completed, positive | "Subsequent to the period end, on 28 July 2025, Alterity announced positive positive topline data from the ATH434-202 open-label Phase 2 clinical trial in individuals with MSA." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1131343/000121390025068955/ea025072501ex99-1_alterity.htm)) |
| late 2026 | [ATH434 trial start](https://sec-api.dev/pdufa/ath434) | ATHE |  | scheduled | ""With the Phase 3 design elements agreed upon, we are executing on our plans to initiate Phase 3 trial activities by year-end 2026."" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1131343/000143774926024928/ex_995835.htm)) |
| July 2029 | [ATH434 primary completion](https://sec-api.dev/pdufa/ath434) | ATHE | Multiple System Atrophy | scheduled | "NCT07729852 (Open-Label Access to ATH434 for Patients Who Completed Study ATH434-201 in France): Overall Status ENROLLING_BY_INVITATION; Phase PHASE2; Primary Completion 2029-07 (ESTIMATED); Lead Sponsor Alterity Therapeutics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07729852)) |
| Jul to Oct 2029 | [ATH434 topline data readout](https://sec-api.dev/pdufa/ath434) | ATHE | Multiple System Atrophy | scheduled | "NCT07729852 (Open-Label Access to ATH434 for Patients Who Completed Study ATH434-201 in France): Overall Status ENROLLING_BY_INVITATION; Phase PHASE2; Primary Completion 2029-07 (ESTIMATED); Lead Sponsor Alterity Therapeutics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07729852)) |

## Drugs

- [ATH434](https://sec-api.dev/pdufa/ath434): advanced msa, multiple system atrophy

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/athe/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "ATHE catalysts: ALTERITY THERAPEUTICS LTD PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/athe/catalysts

```bibtex
@misc{secapidev_companies_athe_catalysts_20261116,
  title        = {ATHE catalysts: ALTERITY THERAPEUTICS LTD PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/athe/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_athe_catalysts_20261116","title":"ATHE catalysts: ALTERITY THERAPEUTICS LTD PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/athe/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
